Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaliproden for oxaliplatin-induced peripheral sensory neuropathy after adjuvant colon cancer chemotherapy
2007-000945-36Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sensory neuropathy (SN) comparing xaliproden hydrochloride with placebo (2 arms). Primary endpoints: Neurological sensory assessment and Complete resolution of peripheral sensory neuropathy at 6 months. Started Jul 2007; status: completed.
02
Drugs
xaliproden
03
Conditions
Sensory neuropathy (SN)
Beyond the preview
Go deeper on 2007-000945-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000945-36.